Clinical Trial Update: Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic and safety study of adalimumab in Chinese subjects with mild rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED